Company
RELX PLC (parent of Elsevier)
Findings that rest on exhibits naming this entity
- INF-3.2: RELX reported 2025 revenue of GBP 2,714m and adjusted operating profit of GBP 1,035m for its Scientific, Technical & Medical segment, which is Elsevier. The report states that Elsevier received more than 4.2 million submissions in 2025, published more than 795,000 articles, and worked with over 37,000 editors and over 1.9 million reviewers.
- INF-3.3: Wiley's fiscal 2024 Form 10-K states that the Hindawi special issues program was suspended in the third quarter of fiscal 2023 because certain special issues contained compromised articles. The Lancet's retraction notice of 5 June 2020 records that three authors requested retraction after the data vendor would not transfer the full dataset for an independent audit and the audit reviewers withdrew.
Exhibits naming this entity
- Exhibit 1022 2025 financial year (annual report published 2026). RELX PLC: RELX Annual Report 2025, Market segments (Scientific, Technical & Medical)
- Exhibit 1024 June 2020. The Lancet (editors): Expression of concern: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis